Onconova Therapeutics Announces Participation in Two Upcoming International Conferences
February 18, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics to Present Update at Noble Capital Markets’ Sixteenth Annual Investor Conference in Hollywood, FL
February 10, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics to Present Update at the 2020 BIO CEO & Investor Conference in New York City
February 04, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics Regains Rigosertib Rights in Greater China
January 23, 2020 08:30 ET
|
Onconova Therapeutics, Inc.
Onconova has the rights to rigosertib, its lead Phase 3 drug candidate, in the key pharmaceutical markets of the United States, Europe, and Greater ChinaThe Company plans to partner certain available...
Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market
January 03, 2020 13:27 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market
December 31, 2019 11:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market
December 19, 2019 13:44 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
December 18, 2019 09:05 ET
|
Onconova Therapeutics, Inc.
Proceeds provide sufficient funds to extend operations and ongoing trials late into the fourth quarter of 2020Company does not intend to raise additional capital for ninety days following the closing...
Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand
December 18, 2019 09:00 ET
|
Onconova Therapeutics, Inc.
Specialised Therapeutics receives exclusive license to commercialize rigosertib in Australia and New ZealandOnconova to be eligible to receive up to US $30.4 million in clinical, regulatory, and...
Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market
December 10, 2019 15:07 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...